What Pharmaron does

Pharmaron is a China-headquartered, Shenzhen-listed (szse:300759) contract research and manufacturing organization (CRO/CDMO) serving the global life sciences industry. Founded in 2004, the company provides fully integrated R&D and manufacturing services spanning small molecules, biologics, cell and gene therapies, ADCs, and protein degraders across the full drug development lifecycle — from target identification and medicinal chemistry through preclinical safety assessment, clinical bioanalysis (including accelerator mass spectrometry), CMC/API manufacturing, and commercial supply. Its core technology platforms include structural biology, DMPK/ADMET, radiolabeled sciences with AMS, high-content screening and cell painting, AAV gene therapy manufacturing, and Watson-LIMS data management, supported by AAALAC-accredited, GLP-compliant facilities across China, the UK, and the US.

The company operates five principal service lines: Laboratory Services (chemistry, biology, DMPK, safety assessment, bioanalysis), Chemistry Manufacturing & Controls (branded as the Pathfinder end-to-end CMC platform), Clinical Development (radiolabeled sciences, early-phase trials, regulatory affairs), Biologics CDMO, and Cell & Gene Therapy CDMO. Specialized platforms include High-Content Screening with cell painting (Operetta, IncuCyte), Integrated Radiolabeled Sciences with LEAMS, Ocular Testing, and Medical Device preclinical services via a 65,000 sq. ft. AAALAC-accredited facility in San Diego. Pharmaron has conducted over 2,000 safety studies and maintains regulatory compliance across FDA, OECD, EMA, NMPA, and MHRA frameworks.

Pharmaron's business model is a hybrid of professional services (CRO) and managed services (CDMO) revenue, with project-specific quote-based pricing across FTE staffing, fee-for-service, milestone-based, and risk-sharing engagement models. Revenue is generated through direct enterprise sales to pharmaceutical, biotechnology, and medical device companies across Asia Pacific, North America, and Europe, leveraging seven global facilities and a 10,000+ employee scientific workforce. Notable customers include Eli Lilly (manufacturing partner for oral GLP-1 orforglipron), and the company pursues scientific thought leadership via active participation in WRIB, SOT, and ELRIG conferences, plus proprietary webinar series and a comprehensive Knowledge Center.

Name

Pharmaron

Legal name

Pharmaron

Website

https://pharmaron.com

Company type

Private

Founded year

2004

Operating status

Operating

Headcount range

5,001–10,000 employees

Short description

Pharmaron is a China-headquartered, publicly listed CRO/CDMO offering fully integrated drug discovery, preclinical, CMC manufacturing, biologics, and cell and gene therapy services to global pharmaceutical, biotechnology, and medical device companies across seven facilities in China, the UK, and the US.

Ownership category

akta.pro rank

Product category

Pharmaceutical Contract Research and Manufacturing (CRO/CDMO)

NAICS

Pharmaceutical and Medicine Manufacturing (3254), Pharmaceutical Preparation Manufacturing (325412), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417), Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Pharmaceutical Preparations (2834), Services-Commercial Physical & Biological Research (8731), Services-Medical Laboratories (8071)

akta.pro primary industry

Drug Substance–Drug Product Integrated CDMO (HLAGABAG)

akta.pro secondary industries

Small-Molecule API & Intermediates CDMO (HLAGABAA), Small-Molecule Drug Product (Solid/Oral/Parenteral) CDMO (HLAGABAB), Gene Therapy (Viral Vector/Plasmid) CDMO (HLAGABAE), Cell Therapy CDMO (HLAGABAD), Clinical CROs (Phase I–IV) (HLAGAAAA)

Keywords

• Contract research services
• Drug discovery services
• CDMO manufacturing services
• Preclinical safety assessment
• Biologics and CGT services

Headquarters

HQ city

Beijing

HQ country

China

HQ region

Asia

Offices6 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Infrastructure, Technology or R&D, Marketing or Sales, Operations, Supply Chain

Revenue model

1. Contract Research Services (CRO): Pharmaron generates revenue through providing integrated drug discovery, preclinical development, and clinical research services on a contract basis. Services include laboratory chemistry, structural biology, in vitro/in vivo biology, DMPK, safety assessment, bioanalysis, and clinical development. Revenue is generated through various commercial models including FTE (full-time equivalent) staffing, fee-for-service, milestone-based payments, and risk-sharing arrangements with pharmaceutical and biotech partners.
2. Contract Manufacturing Services (CDMO): Revenue from API manufacturing and drug product manufacturing services spanning from late-stage clinical through commercial supply. Services include process chemistry, API manufacturing, formulation development, drug product manufacturing, and quality assurance. Manufacturing capabilities support global regulatory requirements across multiple geographies.

Go-to-market motion2 records

Distribution channels1 record

Marketing channels9 records

Core offering

Pharmaron is a contract research organization (CRO) and contract development and manufacturing organization (CDMO) offering fully integrated, end-to-end drug discovery, preclinical, clinical development, and commercial manufacturing services for pharmaceutical, biotechnology, and medical device companies. Core services span laboratory chemistry, biology, DMPK, safety assessment, bioanalysis, small molecule CMC, biologics development, and cell and gene therapy, supported by seven global facilities in China, the UK, and the US.

Product overview

Pharmaron is a premier life science contract research and manufacturing organization (CRO/CDMO) offering comprehensive, fully integrated R&D and manufacturing service capabilities across the entire drug discovery, preclinical, clinical development, and commercialization process. Its service portfolio is organized around five core offerings: (1) Laboratory Services — covering laboratory chemistry (synthetic, medicinal, computational, DNA-encoded libraries, radiolabelling), structural biology, in vitro and in vivo biology, DMPK/ADMET, safety assessment, bioanalysis, medical device testing, and integrated drug discovery; (2) Chemistry, Manufacturing & Controls (CMC) — spanning small molecule drug substance and drug product development, process chemistry, analytical development, API manufacturing, formulation, and late-stage clinical-to-commercial CDMO manufacturing across China, the UK, and the US, branded as the Pathfinder End-to-End CMC Platform; (3) Clinical Development — including integrated radiolabelled sciences with accelerator mass spectrometry (AMS), early phase clinical research (US and China), regulatory affairs, and clinical trial recruitment; (4) Biologics — combining biologics laboratory services (antibody discovery, protein science, biologics PK) with biologics CDMO capabilities (cell line development, process development, drug substance/product manufacturing); and (5) Cell and Gene Therapy (CGT) — encompassing preclinical studies, CGT bioanalysis, analytical testing, and Gene Therapy CDMO (GMP plasmid DNA, viral vectors). These services support all major therapeutic modalities including small molecules, biologics, cell and gene therapies, ADC and other bioconjugates, and protein degraders. Specialized platforms include High-Content Screening with cell painting, Integrated Radiolabelled Sciences with AMS, and Ocular Testing Services with GLP-compliant toxicology.

Differentiator

Problem solved

Functional benefit

Brands

• BioInnovate: Formerly CGT Webinar Series - ongoing collection of webinars focused on cell and gene therapy innovation
• Pharmaron Pathfinder

Products and services

• Laboratory Services Comprehensive suite of discovery and preclinical R&D capabilities including laboratory chemistry (synthetic chemistry, medicinal chemistry, radiolabelling, computer-aided drug design, DNA-encoded libraries), structural biology, in vitro and in vivo biology, DMPK (ADMET), safety assessment, bioanalysis, and integrated drug discovery for pharmaceutical and biotech clients.
• Chemistry, Manufacturing & Controls (CMC) End-to-end small molecule drug substance and drug product development, spanning discovery process chemistry, process chemistry, analytical development, material science, API manufacturing, formulation development, drug product manufacturing, and regulatory filing support, with clinical and commercial-scale manufacturing in China, the UK, and the US.
• Clinical Development Integrated clinical development services including radiolabelled sciences (radiolabelling and radiosynthesis, non-clinical and human ADME with radiolabelled compounds, accelerator mass spectrometry), early phase clinical research in the US, clinical development in China, regulatory affairs, and clinical trial recruitment, supporting global regulatory submissions across FDA, EMA, and NMPA standards.
• Biologics Services End-to-end biologics development including laboratory services (antibody discovery, protein science, biologics PK, safety assessment, large molecule bioanalysis) and biologics CDMO capabilities (IND-enabling services, developability assessment, cell line development, process development, drug substance and drug product manufacturing, analytical services, and quality).
• Cell and Gene Therapy (CGT) Services Cell and Gene Therapy services including preclinical studies (CGT in vivo pharmacology, safety assessment, ophthalmology), CGT bioanalysis (biodistribution, viral shedding, immunogenicity assays), analytical testing services (cell-based potency assays, GMP analytical platforms), and Gene Therapy CDMO (GMP plasmid DNA manufacturing, viral vector process development, product characterization, GMP gene therapy manufacturing, regulatory dossier authoring).
• Medical Device Testing GLP-compliant preclinical surgical and interventional research for medical devices across therapeutic indications including cardiovascular, dental, endoscopy, electrophysiology, general surgery, laparoscopy, metabolic, neuromodulation, neurovascular, orthopedic, ocular, peripheral vascular, reconstruction surgery, robotics, and wound care at the San Diego AAALAC-accredited facility.
• Safety Assessment Safety evaluation of new drug candidates across general toxicology, safety pharmacology, genetic toxicology, developmental and reproductive toxicology (DART), immunotoxicity, and specialty areas including ocular, dermal, medical device, and CGT products, with over 2,000 safety studies conducted to support IND and NDA submissions.
• Bioanalysis GLP and GCP-compliant bioanalytical method development, validation, and sample analysis for small molecules, large molecules, cell and gene therapies, and carbon-14 labeled compounds across discovery through clinical phases, including LC-MS/MS, immunoassay (ELISA, MSD-ECL), flow cytometry, PCR, liquid scintillation counting, and accelerator mass spectrometry.
• Integrated Drug Discovery End-to-end drug discovery programs from hit identification to preclinical candidate selection, combining target identification and validation, high-content screening, computer-aided drug design, structural biology, in vitro and in vivo biology, DMPK, and bioanalysis, with flexible business models including co-piloting, independent delivery, FTE, risk-sharing, and milestone-based services.
• Ocular Testing Services Preclinical ocular drug development including ocular toxicology, ocular efficacy, ocular PK and biodistribution, and ocular device testing, supporting small molecules, biologics, cell therapies (iPSC, RPE), gene therapies (AAV, plasmids), and ocular devices across anterior and posterior segments with OCT, ERG, slit-lamp biomicroscopy, fundus photography, and electroretinography capabilities.
• Pathfinder End-to-End CMC Platform Integrated end-to-end CMC platform integrating API process development and manufacturing, material science, drug product development and manufacturing, analytical development and testing, and regulatory support and quality, supporting clinical development and commercial-scale manufacturing across seven global facilities in China, the UK, and the US.
• Integrated Radiolabelled Sciences Platform Integrated radiolabelled sciences platform combining radiolabelling and radiosynthesis (Carbon-14 and Tritium), non-clinical ADME with radiolabelled compounds, human AME studies, disposition of radiolabelled biologics, and Accelerator Mass Spectrometry (AMS) capabilities for absolute bioavailability and microdosing studies.
• Accelerator Mass Spectrometry (AMS) Ultra-sensitive Accelerator Mass Spectrometry platform for radiolabeled absolute bioavailability studies, microdosing, mass balance, and metabolite profiling, with Low Energy AMS (LEAMS) capabilities enabling reduced complexity workflows, carbon-14 microtracers, and integration with LC for LC+LEAMS workflows aligned with ICH M10 bioanalytical guidelines.
• High-Content Screening (HCS) High-content screening service using automated microscope-based Operetta and IncuCyte systems for hit identification, drug mechanism studies, multiplexed phenotypic readouts, and cell painting applications across 2D, 3D spheroid, and organoid models.
• Cell Painting Assay Service Cell painting assay using six fluorescent dyes to visualize morphological structures with the Operetta High Content Imaging system, supporting phenotypic profiling, target identification and deconvolution, mechanism of action elucidation, and determination of drug resistance mechanisms.
• Gene Therapy CDMO Gene Therapy CDMO providing GMP plasmid DNA manufacturing, viral vector process development, product characterization and QC analytics, GMP gene therapy manufacturing, and regulatory dossier authoring and specification justification for gene therapy products.

Quantifiable outcome

• Over 2,000 safety studies conducted
• +1 more outcomes

Named customers1 record

Segments3 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability8 records

Feature6 records

Partnerships

Four partnerships are on record, tiered major and core.

• Eli LillymajorStrategic or Co-development Partner · 11 March 2026Eli Lilly is investing $3 billion over ten years in China to expand manufacturing capacity for oral solid drugs, including the GLP-1 pill orforglipron. Pharmaron serves as a local manufacturing partner in China for this initiative, collaborating on production expansion alongside Eli Lilly's Suzhou plant investments.
• Biortus BiosciencesmajorStrategic or Co-development Partner · 28 October 2025Pharmaron announced acquisition of 82.54% of Biortus Biosciences in China to strengthen structural biology and drug discovery services. The transaction aims to enhance capabilities in protein science, structural analysis, and AI-driven drug design, expanding Pharmaron's global service platform.
• CGT CatapultcoreStrategic or Co-development PartnerTwo-year collaborative project with Pharmaron Biologics and Complement Therapeutics to intensify perfusion processes and standardize/scale AAV manufacturing for systemic diseases. The partnership leverages Pharmaron's expertise in gene therapy development and manufacturing.
• Complement TherapeuticscoreStrategic or Co-development PartnerJoint development partnership with CGT Catapult and Pharmaron Biologics focused on AAV manufacturing process intensification for systemic gene therapy diseases. Collaboration aims to standardize perfusion processes and enable scalable, cost-effective production.

Scale indicators3 records

Recent moves7 records

Expansion highlights6 records

Broad incumbents

• Thermo Fisher Scientific (PPD): Thermo Fisher's PPD clinical research services and broader life science tools portfolio competes with Pharmaron across discovery, clinical, and bioanalytical services. As a much larger incumbent, Thermo Fisher offers wider scope but less integrated CMC/manufacturing relative to Pharmaron's end-to-end model.
• Eurofins Scientific: Eurofins operates bioanalytical, CMC, and central laboratory services that overlap with Pharmaron's bioanalysis and drug substance testing capabilities. As a broad life sciences testing incumbent, Eurofins serves many of the same pharma and biotech customers with similar analytical workflows.

Direct peers

• Medpace Holdings: Medpace is a mid-sized clinical CRO competing with Pharmaron's clinical development services for biotech and mid-pharma sponsors. While more focused on clinical than discovery/CDMO, Medpace competes in overlapping therapeutic areas and customer segments.
• ICON plc: ICON is a major clinical CRO that competes with Pharmaron's clinical development services for Phase I-IV trials, bioanalytical work, and lab services. Both serve global pharma sponsors with full-service clinical offerings.
• WuXi AppTec: WuXi AppTec is the closest direct peer to Pharmaron, offering end-to-end CRO and CDMO services across small molecules, biologics, and CGT from a similarly China-rooted platform with global facilities. Both companies compete head-to-head for the same biotech and pharma outsourcing dollars and were named alongside each other as key players in the drug discovery services market.
• IQVIA: IQVIA is a global CRO and clinical development services competitor with overlapping offerings in clinical trial management, bioanalysis, and real-world evidence. Pharmaron's clinical development services and radiolabelled sciences platform directly compete for the same pharmaceutical sponsor contracts.
• Labcorp Drug Development (Fortrea): Labcorp Drug Development / Fortrea competes with Pharmaron across clinical CRO services, central labs, and bioanalytical work. The companies serve the same large pharma sponsors for global clinical development and bioanalytical assay validation.
• Charles River Laboratories: Charles River is a leading CRO/CDMO with deep overlap with Pharmaron in safety assessment, bioanalysis, DMPK, and biologics manufacturing. Both companies serve large pharma and biotech with preclinical and CMC services and are regularly cited together as top drug discovery service providers.
• Asymchem Laboratories: Asymchem is a China-based CDMO focused on small molecule API and drug product manufacturing that directly competes with Pharmaron's small molecule CMC and API manufacturing services. Both companies serve global pharma with process chemistry and GMP manufacturing.

Regional players

• Hangzhou Tigermed: Tigermed is a leading China-based clinical CRO that competes with Pharmaron's clinical development offerings, particularly in China-domestic trials and Asia-Pacific sponsor work. Both companies were founded in China and serve overlapping biotech customers in the region.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights7 records

Customer concentration

• Xx.com/pharmaron
• LinkedInlinkedin.com/company/pharmaron
• Instagraminstagram.com/pharmaroncro

Compliance3 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles24 records

Subsidiaries1 record

Funding overview

Funding rounds6 records

Investors6 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A9 records

Investments4 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Pharmaron